PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial
I'm PortAI, I can summarize articles.
PainReform Ltd. is advancing its drop-less OcuRing-K therapy, designed for post-cataract pain and inflammation, toward a Phase II clinical trial in the U.S. in collaboration with LayerBio. The therapy aims to provide consistent control with lower drug exposure than traditional eye drops. Future updates will follow as the program progresses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments